Boston Scientific Launches $2 Billion Accelerated Share Repurchase
Tipranks - Tue May 19, 6:52AM CDT
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Boston Scientific ( (BSX) ).
Boston Scientific on May 18, 2026, entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase as part of its previously announced $5 billion buyback program, initially receiving about 30.4 million shares based on the May 15 closing price of $52.68. The final number of shares will be set using the stock’s volume-weighted average price over the ASR term, with settlement expected by June 30, 2026, leaving $3 billion authorized for future repurchases and an anticipated $0.02 accretion to the company’s adjusted 2026 earnings per share guidance.
The move underscores Boston Scientific’s continued use of shareholder-return strategies alongside its investment in medical technologies that support long-term growth. By reducing its share count through a sizable ASR while maintaining substantial remaining authorization, the company signals confidence in its financial trajectory and balance sheet flexibility, a stance likely to be closely watched by investors assessing capital allocation priorities and earnings leverage.
The most recent analyst rating on (BSX) stock is a Buy with a $96.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Neutral.
The score is anchored by strong underlying financial performance (rising revenue, expanding margins, improving ROE) and a solid—though not flawless—earnings outlook with continued investment and buybacks. This is materially offset by weak technicals (broad downtrend with negative MACD), while valuation appears reasonable at a 17.4 P/E and provides moderate support.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific is a global medical technology company that has spent more than 45 years developing devices and therapies to diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. The company focuses on high-performance solutions aimed at addressing unmet patient needs while helping reduce overall healthcare costs worldwide.
Average Trading Volume: 16,294,763
Technical Sentiment Signal: Sell
Current Market Cap: $78.3B
See more data about BSX stock on TipRanks’ Stock Analysis page.
No comments:
Post a Comment